What Are Peptides? Structure, Function, and What the Science Shows

Summary

• What they are: short chains of amino acids linked by peptide bonds, smaller than proteins and more structurally targeted.
• What they do: most act as signals, binding receptors to trigger a response rather than forming structure.
• Where they come from: your body makes them continuously; they are also synthesized in laboratories and found in food.
• Three regulatory tiers: FDA-approved peptide drugs backed by clinical trials; compounded formulations prepared by licensed pharmacies, which are not FDA-approved; and unapproved research compounds with little or no human data.
• Why the tier matters: safety tracks the tier a compound sits in, not the word "peptide."

Disclosure: Superpower Health facilitates access to compounded semaglutide and compounded tirzepatide through licensed healthcare providers and compounding pharmacy partners. Compounded semaglutide and compounded tirzepatide are NOT equivalent to the branded products. Superpower Health does not sell, prescribe, or facilitate access to any branded version, or to research-only peptides such as BPC-157, TB-500, MOTS-c, and Melanotan II. For information about Superpower's services, see how it works. This educational content is editorially independent.

What are peptides?

A peptide is a chain of amino acids connected by covalent peptide bonds, the same chemical linkages that form proteins, but shorter. The working definition puts a peptide at 2 to 50 amino acids joined in condensation reactions, though the upper bound stretches to 100 depending on the discipline.

Each amino acid has an amino group on one end, a carboxyl group on the other, and a variable side chain that gives it its chemical character. A peptide bond forms when the carboxyl group of one amino acid reacts with the amino group of the next, releasing water and creating a covalent link. The result is a directional chain with a defined beginning and end, and that sequence determines the peptide's shape and, ultimately, what it does. That linear order is the primary structure from which all higher-order biological activity emerges.

Peptides vs. proteins: where the line is

The boundary is a convention, not a sharp biological distinction. The same definitions that cap peptides at 50 amino acids place proteins above that line, with folded three-dimensional structures that enable more complex functions. Insulin illustrates the ambiguity well: it is 51 amino acids across two chains, one residue past the conventional cutoff. It is classified as a peptide hormone all the same, though its size is a fair argument for calling it a small protein instead. GLP-1, by contrast, is 30 amino acids, unambiguously peptide-sized. The functional difference is more useful than the size cutoff: peptides tend to act as signals, proteins as structural scaffolds and enzymes.

| Molecule | Chain length | How the body handles it | Where you meet it | |---|---|---|---| | Amino acid | A single unit | Absorbed directly from digested protein | Food protein, amino acid supplements | | Peptide | 2 to 50 amino acids | Mostly cleaved by digestive enzymes, so most are injected | Hormones your body makes, prescription peptide drugs, skincare | | Protein | Above 50 amino acids, folded into a three-dimensional shape | Broken down into peptides and amino acids before absorption | Dietary protein, enzymes, antibodies |

How peptides work in the body

Most biologically active peptides are signaling molecules. Their specificity comes from receptor binding: a particular sequence recognizes a particular receptor and triggers a downstream cascade. Many peptide hormones act at G protein-coupled receptors, including GLP-1, glucagon, oxytocin, vasopressin, and ghrelin, while others, insulin among them, act at receptor tyrosine kinases. Peptide hormones activate cell-surface receptors to drive metabolic responses through kinase cascades.

GLP-1 shows why that specificity matters. Produced in intestinal L-cells, GLP-1 binds receptors on pancreatic beta cells, triggering insulin secretion and suppressing glucagon in a glucose-dependent manner. That glucose dependence is the reason GLP-1 receptor agonists used on their own carry a low risk of hypoglycemia: the signaling is context-sensitive rather than constant.

Peptides your body already makes

The body synthesizes peptides continuously, and several are foundational to everyday physiology: insulin, which regulates blood glucose; GLP-1, which stimulates insulin release and suppresses appetite; oxytocin, involved in social bonding and childbirth; vasopressin, which controls water reabsorption in the kidney; ghrelin, which drives appetite; and glucagon, which mobilizes stored glucose during fasting. Insulin's structure and receptor-binding mechanisms are mapped in unusual detail, and the body's own peptides became the template for the therapeutic peptide drugs that followed.

Why most peptides can't simply be swallowed

Peptides are broken down by peptidases and proteases (enzymes that cleave peptide bonds), which is why most cannot survive digestion intact and require injection or specialized formulation. Chemical-modification strategies make peptides more drug-like, including cyclization and D-amino acid substitution, both of which resist enzymatic degradation. This is also why an oral peptide supplement and an injectable peptide drug are not comparable products, even when they name the same molecule.

How route changes what a peptide can do

Route of delivery is not a detail of convenience. It decides how much of a peptide reaches its receptor, and therefore what the molecule can plausibly do. Because the gut degrades most peptide bonds, the routes that work are the ones that skip digestion entirely: subcutaneous or intramuscular injection into tissue, intranasal absorption across the nasal mucosa, and topical application that acts locally in the skin. Each route imposes its own ceiling. Injection supports full systemic dosing and is the form nearly all approved peptide medications take. Intranasal delivery works for small, stable molecules. Topical peptides stay largely where they are applied, so the same sequence does very different work in a cream than in a syringe.

• Subcutaneous or intramuscular injection: bypasses digestion. Approved products in this form: insulin, GLP-1 receptor agonists, teriparatide. Evidence base: large randomized human trials.
• Intranasal: bypasses digestion. Approved for small, stable peptides such as desmopressin and calcitonin. Evidence base: approved-indication trial data.
• Topical: bypasses digestion, acts locally in skin. Cosmetic products regulated under cosmetics law, not as drugs. Evidence base: proposed mechanisms, limited human outcome data.
• Oral: does not bypass digestion, degraded by peptidases. Rare; requires absorption enhancers or a non-peptide small molecule. Evidence base: varies by product.

Join 150,000+ others building better health

Get the science behind better health, every week.

SubscribeSigning up...

By clicking “Subscribe” you agree to our Terms of Service and Privacy Policy.

Thanks for signing up!

Check your inbox — your first issue is on the way. We send clinically reviewed health science, never spam.

What peptides are used for

Peptides span an unusually wide range of applications, which is part of why the word is confusing. Short peptides are in use across therapeutic applications, vaccines, and drug delivery alike. FDA-approved peptide drugs are approved for metabolic and hormonal conditions, cancers, and cardiovascular emergencies. The class is larger than most people expect: 60-plus approved peptide drugs, 150-plus in development. Peptides also function as part of the innate immune system, where antimicrobial peptides act as first-line defense molecules, and daptomycin and the polymyxins are approved antibiotics in this class.

Outside prescription medicine, peptides appear in two places most people encounter directly. Hydrolyzed collagen peptides are widely sold supplements, studied in randomized trials for skin and joint outcomes, though the mechanisms proposed for collagen's skin effects are best described as possible rather than established. Topical skincare uses signal, carrier, and enzyme-inhibitor peptides, classified by proposed mechanism in the skin. Cosmetic peptides are regulated under FDA cosmetics law rather than as drugs, so claims are limited to appearance.

What kinds of peptides are there?

For sorting peptides into families, mechanism beats sales channel. Marketing categories mix a molecule class with a delivery route, which is how "collagen," "GLP-1," and "injectable" end up in the same list despite describing three different things. Mechanism gives each peptide a stable identity: a peptide is defined by the receptor it speaks to. Six families cover most of what you will encounter, though they are only a narrow slice of the short peptides now under study. Regulatory status varies enormously within each family, so a shared mechanism says nothing about shared evidence — that question belongs to a different sort entirely.

• Metabolic and incretin: mimics gut hormones that govern insulin release and appetite. Examples: semaglutide, tirzepatide, retatrutide.
• Growth hormone axis: prompts the pituitary to release growth hormone. Examples: sermorelin, tesamorelin, CJC-1295, ipamorelin.
• Immune and antimicrobial: disrupts microbial membranes and modulates immune signaling. Examples: LL-37, thymosin alpha-1.
• Neuro and CNS: acts on receptors involved in mood, stress, and cognition. Examples: Semax, Selank.
• Tissue repair: proposed to influence repair and remodeling; none approved for human use. Examples: BPC-157, TB-500.
• Cosmetic, topical, and food-derived: acts locally in skin, or arrives as a fragment of digested food protein. Examples: GHK-Cu, collagen peptides, dietary protein.

Peptides vs. GLP-1s vs. steroids vs. amino acids

These four terms get collapsed together constantly, and the differences are structural, not semantic. GLP-1 receptor agonists are a subset of peptides, not an alternative to them: semaglutide is built on the backbone of native GLP-1, itself a 30-amino-acid hormone, and behaves like every other signaling peptide. Anabolic steroids are a different chemical class entirely, lipid-derived molecules with a four-ring structure that pass through the cell membrane to act at nuclear receptors. Amino acids are the monomers, the beads rather than the necklace. Supplementing them supplies raw material; it does not deliver a signal.

| Category | Structure | How it acts | Regulatory status | |---|---|---|---| | Peptides | 2 to 50 amino acids in a chain | Binds cell-surface receptors as a signal | Varies: approved, compounded, or unapproved | | GLP-1 receptor agonists | A peptide subset that mimics native GLP-1, a 30-amino-acid hormone | Binds the GLP-1 receptor, a G protein-coupled receptor | FDA-approved prescription drugs | | Anabolic steroids | Lipid-derived, four fused carbon rings, not a chain | Crosses the membrane to act at nuclear receptors | Prescription and controlled substances | | Amino acids | A single unit | Raw material for synthesis, not a signal | Dietary supplements and food |

The three tiers that actually determine what you're getting

For judging safety and evidence, regulatory tier is the sort that matters, not mechanism — tier is what determines the evidence behind a compound. There are three tiers, not two.

• FDA-approved peptide drugs: overseen by FDA review of trials, manufacturing, and labeling. Evidence required: completed clinical trials, plus labeling that describes approved uses, dosing, and risks. Examples: semaglutide, tirzepatide, tesamorelin.
• Compounded formulations: overseen by state-licensed 503A pharmacies, or 503B outsourcing facilities. Compounded under section 503A of the Federal Food, Drug, and Cosmetic Act; not FDA-approved and not evaluated by the FDA for safety, effectiveness, or quality. Examples: compounded semaglutide, compounded tirzepatide.
• Unapproved research compounds: no approval and no enforced manufacturing standards. In most cases no adequate and well-controlled human trials. Examples: BPC-157, TB-500, MOTS-c.

The gap between tiers is not theoretical. FDA has documented adverse events from dosing errors involving compounded semaglutide, including confusion between units and milligrams, a labeling risk the approved-product review process exists to control.

What FDA approval actually means

Approval for a peptide drug requires Phase 1 through Phase 3 clinical trials demonstrating safety and efficacy in the target population, manufacturing standards that ensure consistent identity and purity, and labeling that accurately describes the approved indication, dosage, and risk profile. More than 100 peptides have secured market approval worldwide across multiple disease areas, among them the GLP-1 receptor agonists, teriparatide for osteoporosis, leuprolide for prostate cancer, and eptifibatide for acute coronary syndromes, the last of these designed from barbourin, a protein found in pygmy rattlesnake venom. Labeled indications change over time, and the current label for any approved peptide drug is published on DailyMed.

What the peptide evidence shows, and what it doesn't

Peptides get marketed as one category with one story, but the evidence behind them is nothing like that uniform. The honest way to read any claim is to ask which tier of proof sits behind it, because the distance between an approved indication and a forum anecdote is the entire distinction. Evidence quality varies sharply by claim category, and nothing here is a verdict on an individual compound.

• Weight and metabolic control: FDA-approved indications for semaglutide and tirzepatide rest on large randomized outcome trials.
• Muscle, recovery, and growth hormone axis: approved indications exist for specific medical conditions, not for general performance use — the growth hormone secretagogues CJC-1295 and ipamorelin fall in this tier.
• Skin and hair: randomized human trials exist for oral collagen peptides and topical compounds such as acetyl hexapeptide-8, though the proposed mechanisms are not yet established.
• Topical appearance claims: topical peptides are classified by proposed mechanism in skin; cosmetic regulation limits claims to appearance.
• Immune support: approved antimicrobial peptide drugs exist, but broad "immune boosting" claims made for compounds like LL-37 and thymosin alpha-1 are not supported by human trials.
• Sleep, mood, and cognition: evidence for Semax and Selank is preclinical and small-study only; no FDA-approved peptide carries this indication.
• Tissue repair and remodeling: compounds such as BPC-157 and TB-500 have no approval, no adequate and well-controlled human trials, and no characterized safety profile.

Are peptides safe?

There is no single answer, because "peptide" describes a chemical structure, not a safety profile. Insulin and an unregulated vial bought online are both peptides. What actually determines risk is which tier the compound sits in, how it was manufactured, the delivery route, and the biology of the person using it.

Approved peptide medications have defined safety profiles because they were studied in large trials. For GLP-1 receptor agonists, the cardiovascular, mortality, and kidney outcomes of the class were characterized across eight trials in 60,080 patients with type 2 diabetes, and nausea, vomiting, diarrhea, and constipation are the most common gastrointestinal adverse effects. Those risks are known, labeled, and monitored — including the boxed warning that semaglutide and tirzepatide labels carry for risk of thyroid C-cell tumors, with contraindication in personal or family history of medullary thyroid carcinoma or MEN 2. Findings like these describe the approved products themselves; they do not establish the safety or effectiveness of compounded formulations of the same molecules, which were not studied in those trials.

Unregulated and gray-market peptides

Compounds such as BPC-157, TB-500, MOTS-c, and Melanotan II are not approved by FDA for any human use, have no completed adequate and well-controlled human trials, and carry the most uncertainty about both safety and effectiveness. Registered studies, where they exist, are searchable on ClinicalTrials.gov.

Two failure modes are well documented, and they are separable. The first is purity: related impurities in peptide medicines are a quality-control problem that pharmaceutical-grade production exists to prevent. The second is dosing. One patient who self-administered online-purchased Melanotan II developed rhabdomyolysis and systemic toxicity, spending three days in intensive care, and mass spectrometry confirmed the vial contained exactly what it claimed. The injury came from a dose six times the recommended starting dose, self-selected without supervision. Verified identity is necessary but not sufficient when no labeled dosing regimen exists.

The label alone is a weak basis for judgment, which is why the questions that apply to supplement safety generally — third-party testing and verified identity among them — carry even more weight here.

One point of terminology is widely misunderstood: there is no "research use only" exemption for drugs. RUO is an in-vitro-diagnostic construct under 21 CFR 809.10(c), and a peptide labeled that way has no recognized regulatory status when sold to consumers for human use. BPC-157 is a compound frequently asked about: it does not appear on FDA's 503A Bulks List, FDA has identified it as a bulk drug substance that may present significant safety risks, and its status is under active review as of July 2026.

What long-term peptide safety data is missing

The strongest peptide evidence is still young relative to how these compounds are used. Cardiovascular and kidney outcome trials for the incretin class ran for a few years; people taking them for weight or metabolic reasons often intend to continue far longer, and decade-scale data does not yet exist for any of them. Compounded formulations sit further out again: they were not the products studied in those trials, and no trial has been run on them. For research-tier compounds there is nothing to extrapolate from at all, which is why the open regulatory review of BPC-157 is a live question rather than a settled one. Closing these gaps takes long-duration human trials with prespecified outcomes and controlled manufacturing quality, not accumulated anecdote.

Which biomarkers make peptide effects interpretable

Peptide signaling runs through metabolism, inflammation, and renal clearance, and each of those leaves a trace in routine bloodwork. Capturing those traces first is what turns a later shift into a readable signal rather than a guess.

• Fasting insulin and glucose: core metabolic signaling, and among the most studied outcomes in approved peptide drug trials.
• HbA1c: average blood glucose over roughly three months.
• IGF-1: growth hormone axis activity.
• High-sensitivity CRP: systemic inflammation.
• Lipid panel, including triglycerides: circulating fat handling, monitored during GLP-1 therapy.
• eGFR and ALT: kidney and liver function, both of which affect how peptides are processed and cleared.

All of these are standard clinical blood markers, routinely offered by commercial labs. They are measured by FDA-cleared clinical laboratory methods and by laboratory-developed tests validated under CLIA; laboratory-developed tests are not cleared or approved by the FDA. Derived values such as eGFR are calculated from FDA-cleared results; the derived index itself is not FDA-cleared. Results are used to aid clinician evaluation and are not a stand-alone diagnosis.

Measure your peptide-relevant biomarkers with a Superpower panel

If what sent you researching peptides is a symptom — unexplained weight gain, persistent fatigue, poor metabolic function, or hormonal changes — it deserves clinical evaluation before any compound is considered. A primary care metabolic workup or an endocrinology consultation is the appropriate first step. A symptom is a signal that something in the biology needs attention. A research peptide purchase is not a diagnostic tool.

The principle underlying that approach, understanding your biology before acting on it, is foundational to Superpower's approach to preventive health. In a space where evidence quality ranges from decades of large randomized trials to single rodent studies, a measured baseline is a reliable starting point. The Superpower Baseline Panel covers glucose, HbA1c, high-sensitivity CRP, a lipid panel including triglycerides, ALT, and creatinine in a single draw, with fasting insulin and IGF-1 available on the Advanced Blood Panel. Book your test now, and any later change has something real to be read against.

Safety and regulatory notice

This article discusses peptides as a broad category, including FDA-approved medications and compounds that are not FDA-approved for any human use. Not all peptides discussed carry the same evidence base or safety profile.

Superpower Health does not sell, prescribe, dispense, or arrange access to BPC-157, TB-500, MOTS-c, Melanotan II, or other research-only compounds. Superpower Health facilitates access to compounded formulations of certain prescription peptide medications, including semaglutide and tirzepatide, through licensed healthcare providers and compounding pharmacy partners; see the informed consent for semaglutide and tirzepatide. Compounded drugs are not FDA-approved, have not been evaluated by the FDA for safety, effectiveness, or quality, and are not generic versions, substitutes, or equivalents of the approved products. They have not been shown to be as safe or as effective as the approved products, and they are not dispensed with FDA-approved labeling; they may not include the boxed warning or Medication Guide that accompanies the approved product. Adverse events and product quality problems should be reported to the dispensing pharmacy and to FDA MedWatch.

FDA-approved peptide medications are prescription drugs that must be obtained through a licensed healthcare provider. Research-only peptides are not regulated for human safety, efficacy, or manufacturing quality, and products purchased through unregulated channels may contain incorrect doses, contaminants, or misidentified compounds.

This content is for educational and informational purposes only and is not a substitute for medical advice, diagnosis, or treatment. Consult a licensed healthcare provider. Do not obtain or self-administer any research-only compound.

All product names referenced are trademarks of their respective owners. Superpower Health is not affiliated with, endorsed by, or sponsored by any of these manufacturers.